NeuroMetrix, Inc. NURO
Set alert
4.58 USD 0.00 0.00%
At close · May 1
4.33 Day range 4.69
2.66 52-week range 4.73
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 4.36
- Prev close
- 4.58
- Mkt cap
- 8.07M
- Vol
- 35.59K
- Avg vol
- 21.57K
- EPS
- -4.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.33
- High
- 4.69
- Forward P/E
- 9.88
- Beta
- 2.30
- Short ratio
- 1.52
- Inst. own
- 3.01%
- Dividend
- 0.00
- Ex-div date
- Mar 27, 2007
- 50-d avg
- 4.05
- 200-d avg
- 3.91
- 1y target
- 0.00
2Y chart
Events in this range
- Jul 27, 2023Earnings: -1.52; estimate 0; surprise —%
- Oct 26, 2023Earnings: -1.68; estimate 0; surprise —%
- Nov 22, 2023Split: 1 for 8
- Feb 22, 2024Earnings: -1.43; estimate 0; surprise —%
- May 15, 2024Earnings: -1.67; estimate 0; surprise —%
- Aug 6, 2024Earnings: -0.74; estimate 0; surprise —%
- Nov 5, 2024Earnings: -0.75; estimate 0; surprise —%
Signals (83)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | May 1, 2025 | 1 year ago |
| MACD: Buy Signal | May 1, 2025 | 1 year ago |
| SMA: Bearish | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 10, 2025 | 1 year ago |
| SMA: Bearish | Apr 9, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| RSI: Overbought | Mar 24, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 20, 2025 | 1 year ago |
| RSI: Overbought | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bullish | Jan 17, 2025 | 1 year ago |
| SMA: Bearish | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| SMA: Bearish | Dec 12, 2024 | 1 year ago |
| SMA: Bearish | Dec 10, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 10, 2024 | 1 year ago |
| SMA: Bullish | Dec 4, 2024 | 1 year ago |
| SMA: Bearish | Dec 3, 2024 | 1 year ago |
| SMA: Bullish | Nov 20, 2024 | 1 year ago |
| SMA: Bullish | Nov 19, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 19, 2024 | 1 year ago |
| SMA: Bearish | Nov 18, 2024 | 1 year ago |
| SMA: Bullish | Nov 15, 2024 | 1 year ago |
| SMA: Bearish | Nov 8, 2024 | 1 year ago |
| SMA: Bullish | Nov 7, 2024 | 1 year ago |
| SMA: Bearish | Nov 5, 2024 | 1 year ago |
| SMA: Bearish | Oct 31, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 24, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 16, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 9, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 1, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 19, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| SMA: Bearish | Aug 23, 2024 | 2 years ago |
| SMA: Bullish | Aug 22, 2024 | 2 years ago |
| SMA: Bearish | Aug 21, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 16, 2024 | 2 years ago |
| RSI: Oversold | Aug 7, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 30, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 3, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 2, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 18, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 13, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 12, 2024 | 2 years ago |
| SMA: Bearish | May 17, 2024 | 2 years ago |
| SMA: Bearish | May 15, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| MACD: Sell Signal | May 9, 2024 | 2 years ago |
| SMA: Bearish | Apr 30, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 19, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 27, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 26, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 22, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 14, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Feb 21, 2024 | 2 years ago |
| SMA: Bullish | Feb 15, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| SMA: Bullish | Feb 12, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 10, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 14, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 8, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| RSI: Oversold | Oct 31, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 26, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 29, 2023 | 3 years ago |
| RSI: Oversold | Sep 26, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 25, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 5, 2023 | 3 years ago |
| RSI: Oversold | Aug 24, 2023 | 3 years ago |
| RSI: Oversold | Aug 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 28, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 19, 2023 | 3 years ago |
Key statistics
- Market cap
- 8.07M
- Enterprise value
- -7.03M
- Trailing P/E
- 0.00
- Forward P/E
- 9.88
- PEG ratio
- 0.00
- Price / sales
- 2.14
- Price / book
- 0.49
- EPS (TTM)
- -4.51
- Beta
- 2.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -203.71%
- Revenue (TTM)
- 3.77M
- Revenue growth
- -51.20%
- Free cash flow
- 0
- Total cash
- 14.83M
- Total debt
- 0
- Return on equity
- -42.78%
- Shares outstanding
- 2.04M
- Short % of float
- 1.54%
- 50-day average
- 4.05
- 200-day average
- 3.91
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NURO Revenue — quarterly 582.82K
NURO Net income — quarterly -1.78M
NURO EPS — quarterly -0.86
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.00 | -0.75 | — | — |
| Aug 6, 2024 | Jun 1, 2024 | 0.00 | -0.74 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.67 | — | — |
| Feb 22, 2024 | Dec 1, 2023 | 0.00 | -1.43 | — | — |
| Oct 26, 2023 | Sep 1, 2023 | 0.00 | -1.68 | — | — |
| Jul 27, 2023 | Jun 1, 2023 | 0.00 | -1.52 | — | — |
About NeuroMetrix, Inc.
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- neurometrix.com
News
- electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
- NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
- NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
- electroCore Enters Definitive Deal To Acquire NeuroMetrix, Including Its Quell Platform
- NeuroMetrix to be Acquired by electroCore
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
- NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
- NeuroMetrix Reiterates its Review of Strategic Alternatives
- NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
Your note
Sign in to keep a note on NURO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FLUEGEL BRADLEY M | Director | Conversion of Exercise of derivative security | Apr 29, 2024 | 8,634 |
| GOODMAN DAVID E | Director | Conversion of Exercise of derivative security | Apr 29, 2024 | 7,602 |
| GOZANI SHAI N | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 31, 2024 | 13,812 |
| HIGGINS THOMAS J | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 31, 2024 | 10,633 |
| HIGGINS THOMAS T | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 1, 2023 | 47,868 |
| HOROWITZ JOSHUA S | Director | Sale | Apr 21, 2024 | 83,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mariner, LLC | 0.76% | 15,457 | 61.05K | Sep 29, 2024 |
| Vanguard Group Inc | 0.74% | 15,124 | 59.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 13,819 | 54.59K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.42% | 8,560 | 33.81K | Sep 29, 2024 |
| Blackrock Inc. | 0.25% | 5,013 | 19.80K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,458 | 5.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.74% | 15,124 | 59.74K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 8,866 | 35.02K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 2,172 | 8.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 1,867 | 7.37K | Oct 30, 2024 |